{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:52:59Z","timestamp":1791021179536,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.urolonc.2026.08.016","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:17:32Z","timestamp":1790727452000},"page":"960-967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-0603","authenticated-orcid":false,"given":"Todd M.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halit O.","family":"Yapici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4409-6265","authenticated-orcid":false,"given":"Jonathan","family":"Lilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3964-2185","authenticated-orcid":false,"given":"Weiqi","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-5206","authenticated-orcid":false,"given":"Kunal","family":"Lodaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.08.016_bib0001","series-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer","author":"van der Heijden HMB","year":"2026"},{"issue":"22","key":"10.1016\/j.urolonc.2026.08.016_bib0002","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.016_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.urolonc.2026.08.016_bib0004","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab Vedotin and Pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.016_bib0005","doi-asserted-by":"crossref","unstructured":"Galsky MD, Valderrama BP, Maruzzo M, Pous AF, Ciuleanu TE, Chatzkel JA, et al. Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study. J Clin Oncol 2026;44(7 suppl.): LBA630. https:\/\/doi.org\/10.1200\/JCO.2026.44.7_ suppl.LBA630","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630"},{"key":"10.1016\/j.urolonc.2026.08.016_bib0006","unstructured":"Centers for Medicare & Medicaid Services. Local coverage determination (LCD): moldx: minimal residual disease testing for cancer; 2021. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=38779&ver=4."},{"issue":"24","key":"10.1016\/j.urolonc.2026.08.016_bib0007","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.016_bib0008","doi-asserted-by":"crossref","first-page":"609","DOI":"10.6004\/jnccn.2023.7011","article-title":"Private payer and Medicare coverage policies for use of circulating tumor DNA tests in cancer diagnostics and treatment","volume":"21","author":"Douglas","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.016_bib0009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12935-025-03707-z","article-title":"Prognostic and predictive role of circulating tumor DNA detection in patients with muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"25","author":"Gao","year":"2025","journal-title":"Cancer Cell Int"},{"issue":"23","key":"10.1016\/j.urolonc.2026.08.016_bib0010","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.016_bib0011","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant Atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.08.016_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1221718","article-title":"Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay","volume":"13","author":"Powles","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.016_bib0013","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/BLC-170140","article-title":"Liquid biopsy-analysis of circulating tumor DNA (ctDNA) in bladder cancer","volume":"4","author":"Todenhofer","year":"2018","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.08.016_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040803","article-title":"New perspectives on the role of liquid biopsy in bladder cancer: applicability to precision medicine","volume":"16","author":"Alberca-Del Arco","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.016_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432054","article-title":"Advancements in urothelial cancer care: optimizing treatment for your patient","volume":"44","author":"Hemenway","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"18","key":"10.1016\/j.urolonc.2026.08.016_bib0016","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.016_bib0017","unstructured":"Medicare extends coverage of Natera\u2019s Signatera\u2122 MRD test to muscle invasive bladder cancer [Internet]; 2022. Available from:https:\/\/www.natera.com\/company\/news\/medicare-extends-coverage-of-nateras-signatera-mrd-test-to-muscle-invasive-bladder-cancer\/"},{"key":"10.1016\/j.urolonc.2026.08.016_bib0018","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.urology.2025.03.028","article-title":"Real-world economic burden and healthcare resource utilization of radical cystectomy and trimodal therapy for bladder cancer in the United States","volume":"200","author":"Williams","year":"2025","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.016_bib0019","doi-asserted-by":"crossref","DOI":"10.1097\/JU9.0000000000000286","article-title":"Real-world study of short-term and long-term clinical outcomes with radical cystectomy for bladder cancer in the United States","volume":"3","author":"Williams","year":"2025","journal-title":"JU Open Plus"},{"issue":"4","key":"10.1016\/j.urolonc.2026.08.016_bib0020","doi-asserted-by":"crossref","first-page":"165.e17","DOI":"10.1016\/j.urolonc.2021.09.013","article-title":"Defining radical cystectomy using the ICD-10 procedure coding system","volume":"40","author":"Lyon","year":"2022","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.08.016_bib0021","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"24","key":"10.1016\/j.urolonc.2026.08.016_bib0022","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant Atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.016_bib0023","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur Urol"},{"issue":"224","key":"10.1016\/j.urolonc.2026.08.016_bib0024","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.urolonc.2026.08.016_bib0025","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.urolonc.2026.08.016_bib0026","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by Ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.08.016_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13100312","article-title":"Real-world technical hurdles of ctDNA NGS analysis: lessons from clinical implementation","volume":"13","author":"Cabello-Aguilar","year":"2025","journal-title":"Diseases"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.016_bib0028","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40291-021-00559-x","article-title":"Commercial ctDNA assays for minimal residual disease detection of solid tumors","volume":"25","author":"Chen","year":"2021","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.urolonc.2026.08.016_bib0029","series-title":"Payer coverage policies of tumor biomarker and pharmacogenomic testing","year":"2023"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.016_bib0030","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-471912","article-title":"Current and future role of circulating DNA in the diagnosis and management of urothelial carcinoma","volume":"45","author":"Bellmunt","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.urolonc.2026.08.016_bib0031","article-title":"Testing the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy after surgical removal of the bladder, kidney, ureter, and urethra for urothelial cancer treatment, MODERN study","year":"2026","journal-title":"National Cancer Institute"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:56:48Z","timestamp":1791017808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926007118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1078143926007118"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}